Retatrutide LY3437943
Exploring the science of triple-receptor agonism and the interconnected pathways involved in metabolic regulation, glucose homeostasis, and energy balance.
What Is Retatrutide?
Retatrutide (LY3437943) is a synthetic peptide investigated for its ability to activate three hormone receptors involved in metabolic regulation: GIP, GLP-1, and glucagon receptors.
Its triple-agonist pharmacology makes it a subject of scientific interest for understanding how multiple hormonal signaling systems interact to regulate glucose metabolism, lipid utilization, and energy homeostasis.
Three Receptors. Interconnected Pathways.
Retatrutide activates three distinct G protein-coupled receptor systems. Each contributes to metabolic regulation through different physiological mechanisms.
GIP Receptor
Involved in nutrient-responsive hormonal signaling, glucose-dependent insulin secretion, and metabolic regulation. Researchers examine its relationship with pancreatic beta-cell activity and nutrient metabolism.
GLP-1 Receptor
Associated with glucose-dependent insulin secretion, glucagon regulation, gastrointestinal motility, and central appetite-related signaling.
Glucagon Receptor
Involved in hepatic glucose production, lipid metabolism, and energy regulation. Research explores its role in metabolic substrate utilization and energy expenditure.
Research Applications
Retatrutide is investigated across multiple areas of metabolic and endocrine science.
Metabolic Signaling
Interactions among GIP, GLP-1, and glucagon receptor pathways.
Glucose Homeostasis
Hormonal mechanisms influencing glucose metabolism and insulin signaling.
Lipid Metabolism
Pathways involved in lipid utilization and metabolic substrate regulation.
Energy Homeostasis
Relationships between endocrine signaling and energy balance.
Receptor Pharmacology
Receptor selectivity, agonist activity, and downstream cellular signaling.
Endocrine Interactions
How multiple hormonal pathways coordinate physiological responses.
Scientific Background
Retatrutide was developed by Eli Lilly and Company and has been evaluated in clinical research programs investigating metabolic conditions.
A Phase 2 clinical trial published in the New England Journal of Medicine in 2023 contributed to scientific understanding of triple-receptor agonism and informed subsequent investigations.
Findings from pharmaceutical clinical trials relate specifically to the investigational materials and controlled conditions used in those studies.
Published findings do not establish the identity, purity, safety, or equivalence of independently supplied research materials.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff AM, et al. New England Journal of Medicine. 2023;389:514–526.
View Scientific Publication ↗Product Specifications
General compound information and listed research material characteristics. Batch-specific analytical documentation should be consulted where available.
Storage & Laboratory Handling
Retatrutide research material should be stored and handled in accordance with documented supplier specifications and applicable laboratory safety procedures.
Researchers should consult available batch-specific documentation for storage recommendations, stability information, and handling requirements.
Appropriate protective equipment and established laboratory protocols should be used when handling investigational research compounds.
For Laboratory Research Only
Retatrutide is an investigational compound and is not FDA-approved for clinical use.
Materials supplied by Titan Helix Biosciences are designated for laboratory research and analytical investigation only. They are not represented as pharmaceutical products or as equivalent to compounds used in published clinical trials.
Not for human or veterinary use. Not intended for administration, consumption, diagnosis, treatment, prevention, or cure of any disease.
Research materials should be handled only by appropriately qualified laboratory personnel in suitable research environments.